Insights

Home » Insights » Insights Intercept Blood System

Categories

see all
Cerus 30/08/2019

Transfusion of a false negative NAT HIV-infected blood donation does not lead to transmission in platelet recipients

In France, since 2010, the risk of HIV transmission by transfusion is reduced by the use of individual NAT.

Despite this testing approach, a false negative test result was obtained from a 57-year-old male repeat donor in March 2017, using the ProcleixUltrio assay. A repository sample from that donation tested positive with the Cobas Taqman HIV-1 (limit of detection at 95%, 17 copies/mL).
Cerus 22/07/2019

ISBT Basel 2019 - Presentations

PresentationsCerus Satellite Symposium at ISBT Basel 2019

"Safeguarding the blood supply against (re)emerging pathogens. Balancing blood safety and economics"

Have you had the opportunity to join Cerus Satellite symposium on Tuesday June 25, 2019 at the ISBT in Basel? Regardless, we are pleased to share the presentations with you from the Cerus Symposium. 
Transfusion-Transmitted Infections 18/02/2019

INTERCEPT Blood System may prevent transmission of occult Hepatitis B infection

The paper by Candotti et al. describes HBV transmission to 9 (nine) recipients by blood transfusion with FFP and RBC components from 3 (three) Slovenian blood donors with occult hepatitis B infection (OBI). The viruses remained undetected by both serology (HBsAg) and NAT testing.
Transfusion-Transmitted Infections 07/01/2019

INTERCEPT Blood System supports blood supply during West Nile virus epidemic in France

Since the beginning of July 2018, the Mediterranean region has experienced an epidemic of West Nile virus infections: 24 cases in three French regions (Paca, Corsica and Occitania), according to the latest report from Public Health France. The disease is transmitted by the Culex mosquito.
Transfusion-Transmitted Infections 06/11/2018

Platelet transfusion-associated bacterial sepsis cases reported in Utah and California

The US Department of Health and Human Services, Centers for Disease Control (CDC) recently published details related to fatal sepsis cases that resulted from bacterially contaminated conventional platelet components.
Regulations 08/08/2018

Pathogen Inactivation, towards becoming the standard of care in Germany

As of January 1, 2018, specific reimbursement for pathogen inactivated platelets is now available in Germany.

Ask an Expert

Do you have questions about the INTERCEPT™ Blood System, blood safety or blood transfusions? The INTERCEPT team has plenty of knowledge and expertise.

Ask an Expert

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 00157 v43.0